Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection

Health systems need a better way to deliver cancer screening.

Too many eligible patients remain unscreened despite a growing list of cancer screening options. Freenome is partnering with health systems to build a more personalized and connected approach to screening.
Start the Conversation

Health systems need a better way to deliver cancer screening.

Too many eligible patients remain unscreened despite a growing list of cancer screening options. Freenome is partnering with health systems to build a more personalized and connected approach to screening.
Start the Conversation

Be at the forefront
of a new cancer
screening paradigm

Transform how your patients get screened with a single blood draw and digital tools. Freenome’s health system solution integrates testing and workflows to help close the gap in cancer screening.

Get Started Now

Be at the forefront
of a new cancer
screening paradigm

Transform how your patients get screened with a single blood draw and digital tools. Freenome’s health system solution integrates testing and workflows to help close the gap in cancer screening.

Get Started Now

Be at the forefront
of a new cancer
screening paradigm

Transform how your patients get screened with a single blood draw and digital tools. Freenome’s health system solution integrates testing and workflows to help close the gap in cancer screening.
Get Started Now

Expand participation. Build for what's next.

The challenge isn’t choosing between today’s screening approaches and tomorrow’s. It’s building screening programs that help more eligible patients benefit from appropriate screening while preparing for what’s ahead.

Personalized screening. Connected care.

Helping more eligible patients benefit from appropriate screening takes more than new screening options. It requires a more personalized and connected approach to cancer screening.

Personalized Cancer Detection

Freenome's approach to blood-based cancer screening combines risk-based screening with indication-specific tests, all through a simple blood draw.

Freenome
Digital Health

EHR-native digital tools that help health systems identify eligible patients, engage patients and care teams, and integrate screening into routine care.

What this means for health systems

Together, Personalized Cancer Detection and Freenome Digital Health are designed to help health systems address three persistent challenges in cancer screening.
Card 1 front
Card 2 front
Card 2 back
Card 3 front
Card 3 back

Help shape what's next in cancer screening

As a Founding Partner, your health system will collaborate with Freenome to help shape what’s next in cancer screening. You’ll begin with SimpleScreen Lung and SimpleScreen CRC, with additional screening needs supported as the SimpleScreen portfolio grows. You’ll also have access to Freenome Digital Health.

What you'll receive as a Founding Partner

Program Design and Optimization

Implementation guidance, clinical and EHR workflow optimization, and digital tools tailored to your health system

Evidence Generation

Collaborate on real-world evidence, publications, and shared insights

Expanding Portfolio

Early access to additional SimpleScreen indications as the portfolio expands

Shape What’s Next

Help shape what’s next in cancer screening and how it’s delivered

Ready to help shape what’s next?

Join a select group of health systems helping shape what’s next in cancer screening. Founding Partner opportunities are limited.
Apply now

1. NORC at the University of Chicago. (2022). Percent of Cancers Detected by Screening in the U.S. Available at https://cancerdetection.norc.org
2. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10-45. doi:10.3322/caac.21871

You are leaving this website

By selecting this link, you are leaving the Freenome website and will be directed to another web page.

Continue
Cancel